The therapeutic landscape for rheumatoid arthritis (RA) has undergone a profound transformation over the last decade, marked by the emergence of Janus kinase inhibitors (JAKi) as highly effective agents capable of challenging the long-standing dominance of biological disease-modifying antirheumatic drugs[1]. Their rapid incorporation into clinical practice, however, was followed by a phase of regulatory restriction, most notably after the European Medicines Agency (EMA) issued recommendations aimed at minimizing the risk of major cardiovascular events, malignancy, venous thromboembolism, and serious infections in selected patient populations[2].
